Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBS-20 is a standardized Chinese herbal formulation composed of aqueous extracts from 20 different medicinal herbs. It is developed as a potential therapeutic agent for the treatment of irritable bowel syndrome (IBS). The formula is produced under good manufacturing practices (GMP), with each herb botanically and chemically authenticated. The mixture undergoes water extraction, concentration, and spray drying to yield a powder that is then formulated with water-soluble starch as an excipient. Chemical standardization uses liquid chromatography-mass spectrometry (LC-MS) with reference markers for quality assurance. The mechanism of action likely involves multiple pathways relevant to gastrointestinal function and inflammation, but specific molecular targets are not detailed in the available literature[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on IBS-20.